DermTech Inc. to Pay Up to $5M to Resolve Allegations It Submitted False Claims to Medicare for Unreliable Skin Cancer Tests
A skin cancer testing company formerly known as DermTech, Inc. has agreed to settle allegations that it violated the False Claims Act by knowingly submitting false claims for unreliable skin cancer tests to the Medicare program. DermTech is now liquidating as DTech Liquidating Inc. after filing for Chapter 11 bankruptcy in the District of Delaware in June 2024. As part of the resolution announced today, the...
Contenu original affiche; la traduction localisee n'est pas encore disponible.
Ce qui s'est passé
A skin cancer testing company formerly known as DermTech, Inc. has agreed to settle allegations that it violated the False Claims Act by knowingly submitting false claims for unreliable skin cancer tests to the Medicare program. DermTech is now liquidating as DTech Liquidating Inc. after filing for Chapter 11 bankruptcy in the District of Delaware in June 2024. As part of the resolution announced today, the...
Pourquoi c'est important
The development may change operating conditions or market expectations around Regulation. Further confirmation and measurable outcomes matter.
Entités concernées
Voir les preuves
2 articles · 1 publication d'origine · 1 independantes
- U.S. Department of JusticeSource primaire · Confirme · EN · 100%DermTech Inc. to Pay Up to $5M to Resolve Allegations It Submitted False Claims to Medicare for Unreliable Skin Cancer Tests ↗
- U.S. Department of JusticeSource primaire · Confirme · EN · 80%DermTech Inc. to Pay Up to $5M to Resolve Allegations It Submitted False Claims to Medicare for Unreliable Skin Cancer Tests ↗
Affirmations
- DermTech Inc. to Pay Up to $5M to Resolve Allegations It Submitted False Claims to Medicare for Unreliable Skin Cancer Tests Observé
Divergences
Aucune divergence importante détectée dans les preuves disponibles.
Chronologie
- Premier signalement
Mouvement de marché suivant l'événement
La réaction du marché n'est pas encore disponible pour cet actif et cette fenêtre.